47.78
0.63 (1.34%)
| Previous Close | 47.15 |
| Volume | 3,113,499 |
| Price / Sales | 15.01 |
| Price / Book | 134.18 |
| 52 Weeks Range |
| Profit Margin | -26.41% |
| Operating Margin (TTM) | 70.24% |
| Diluted EPS (TTM) | -1.24 |
| Quarterly Revenue Growth (YOY) | -29.60% |
| Total Debt/Equity (MRQ) | 108.23% |
| Current Ratio (MRQ) | 5.15 |
| Operating Cash Flow (TTM) | 61.15 M |
| Levered Free Cash Flow (TTM) | -6.46 M |
| Return on Assets (TTM) | -5.86% |
| Return on Equity (TTM) | -26.22% |
News Mood
-
Arrowhead Pharmaceuticals Q4 Earnings Call Highlights
12 Nov, 8:14PM
-
Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
07 Nov, 3:15PM
-
Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
04 Nov, 6:30AM
-
Arrowhead Research: Fiscal Q4 Earnings Snapshot
12 Nov, 3:22PM
-
Arrowhead Pharmaceuticals falls on earnings miss
12 Nov, 4:03PM
AIStockmoo Score
| Value 30% | -1.4 |
| Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Return on Capital info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | -3.1 |
| Uptrend over the past year. Far below its 52-week high. info | |
| In a downtrend: the price is below its moving averages, and they are falling. It has dropped well below them. A recent move above resistance has not been confirmed. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | -0.1 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mixed or neutral. info | |
| Holdings' Sentiment info | NA |
| Smart Money 20% | 1.4 |
| Institutions net +1.69% of shares in their latest 13F filings: 257 holders increased, 268 decreased (quarter to 30 Sep 2026). info | |
| Short interest +22.9% from 31 Aug to 30 Oct 2026, 8.5 days to cover (FINRA). info | |
| Insider Activity info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Earnings per share have gone up and down. Made a loss in recent years. info | |
| Below its medium-term trend line. info | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Short-term momentum falling. info | |
| No clear signal from support and resistance. info | |
| Final Score | -1.29 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Arrowhead Pharmaceuticals, Inc. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| ARWR | - | - | - | 134.18 | -1.3 |
| SYRE | 9 B | - | - | 10.08 | 1.1 |
| MDGL | 9 B | - | - | 14.74 | -0.4 |
| CORT | 7 B | - | 47.78 | 8.89 | -1.5 |
| FOLD | 5 B | - | - | - | 0.0 |
| ARQT | 3 B | - | 119.82 | 14.26 | -0.1 |
Select this tab to load the latest available analysis.
|
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 13.02% |
| % Held by Institutions | 77.19% |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 96.54%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 257 | 14,798,342 |
| Decreased | 268 | 13,553,768 |
| New | 83 | 4,488,008 |
| Sold out | 84 | 3,346,457 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 11,583,518 | 8.5 |
| 15 Oct 2026 | 10,959,276 | 5.4 |
| 30 Sep 2026 | 10,760,463 | 4.0 |
| 15 Sep 2026 | 9,272,290 | 5.1 |
| 31 Aug 2026 | 9,426,449 | 8.8 |
| 14 Aug 2026 | 9,207,426 | 7.8 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 13 Nov 2026 | Yahoo Finance |
Arrowhead (ARWR) Q4 2026 Earnings Call Transcript
Plozasiran launch prep and a multibillion sHTG opportunity come into focus. |
| 12 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals Q4 Earnings Call Highlights
Arrowhead Pharmaceuticals (NASDAQ:ARWR) is preparing for a potential U.S. launch of its drug REDEMPLO in a larger patient population in the second quarter of 2027, as the company works to turn growing prescription demand for the medicine into paid treatments. On its fiscal 2026 earnings call, manag… |
| 12 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals falls on earnings miss
Investing.com -- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) reported fiscal year 2026 results that fell short of Wall Street expectations, with the stock declining 2.4% in after-hours trading Thursday. |
| 12 Nov 2026 | Yahoo Finance |
Arrowhead Research: Fiscal Q4 Earnings Snapshot
(AP) — Arrowhead Research Corp. (ARWR) on Thursday reported a loss of $428 million in its fiscal fourth quarter. |
| 12 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results
PASADENA, Calif., November 12, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2026 fiscal year ended September 30, 2026. The Company is hosting a conference call today, November 12, 2026, at 4:30 p.m. ET to discuss the results. |
| 09 Nov 2026 | Yahoo Finance |
Is Arrowhead Pharmaceuticals (ARWR) Worth Its Price After UK Approval?
Arrowhead Pharmaceuticals has had a bumpy share price journey lately, which puts a fresh spotlight on one simple question for investors who follow drug developers that rely heavily on future product uptake: is today’s valuation supported by its sales base? Over the past 3 years the stock has… |
| 09 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
PASADENA, Calif., November 09, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:… |
| 07 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
PASADENA, Calif., November 07, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. The presentations included… |
| 04 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
PASADENA, Calif., November 04, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs, improves near-term liquidity, extends its debt maturity, and increases financial and… |
| 03 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
PASADENA, Calif., November 03, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 12, 2026, at 4:30 p.m. ET to discuss its financial results for the 2026 fiscal year ended September 30, 2026… |
| 02 Nov 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
PASADENA, Calif., November 02, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week’s American Heart Association Scientific Sessions in Chicago. |
| 31 Oct 2026 | Yahoo Finance |
3 Biotech Stocks With Upside Of Up To 80%
Tech heavy indices have taken a hit as investors question huge AI spending, which leaves many traders searching for growth stories that are tied less to data centers and more to hard science. That is where high risk, high potential biotech stocks with solid finances come into focus. This article… |
| 28 Oct 2026 | Yahoo Finance |
Arrowhead gains UK marketing authorisation for Redemplo
The regulatory approval covers patients diagnosed through either genetic testing or clinical criteria. |
| 27 Oct 2026 | Yahoo Finance |
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
PASADENA, Calif., October 27, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial Chylomicronaemia Syndrome (FCS) will have access to a newly licensed new treatment option available on the NHS… |
| 23 Oct 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own
Biotech stocks live and die on access to capital, so the Federal Reserve’s signal that interest rates may pause for now gives this high risk corner of the market some breathing room. Cheaper money can make it easier to fund drug pipelines and clinical trials, which matters if you are hunting for… |
| 16 Oct 2026 | Yahoo Finance |
Arrowhead Pharmaceuticals (ARWR) Reports Fresh ARO MAPT Data, Is The Stock Still Cheap?
Arrowhead Pharmaceuticals (ARWR) drew fresh attention after announcing interim Phase 1/2a data for ARO-MAPT, which showed deep and durable cerebrospinal fluid tau reductions in healthy volunteers using subcutaneous RNA interference delivery across the blood brain barrier. Arrowhead Pharmaceuticals… |
| 15 Oct 2026 | Yahoo Finance |
ARWR: Interim ARO-MAPT Data Shows Potential for TRiM™ Platform in CNS Diseases
By David Bautz, PhD NASDAQ: ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Interim Data for ARO-MAPT Shows Promise for TRiM™ Platform in CNS Diseases On October 14, 2026, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced interim results for the Phase 1/2a study of ARO-MAPT, which is… |
| Show more | ||
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |